Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

British Journal of Cancer

Volumn 76, Issue 10, 1997, Pages 1376-1381

  Punt, C J A ^a   Voest, E E ^b   Tueni, E ^c   Van Oosterom, A T ^d   Backx, A ^a   De Mulder, P H M ^a   Hecquet, B ^e   Lucas, C ^f   Gerard, B ^f   Bleiberg, H ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Hospital de Jolimont   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Center Oscar Lambret   (France)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^g JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MULTIDRUG RESISTANCE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; STOMATITIS; VOMITING;

EID: 9844260525     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.563     Document Type: Article

References (37)

1. Awada A, Pagani O, Piccarl M, Leyvral S, Cerny T, Sessa C, Cavalli E Coquoz D, Marinus W and Gerard B (1993) Phase I clinical and pharmacokinetic trials of S978S alone and in combination with adriamycin. (Abstract) Proc Am Assoc Cancer Res 34: 213
2. Bakes DM, Turner ND, Gordon BH, Hiley MP and Walther B (1993) Method for the analysis of S9788. a drug to reverse resistance to anticancer agents, in animal plasms and human plasma and serum by high-performance liquid chromatography with ultraviolet detection, J Chromatogr 615: 117-126
3. Bartlett NL, Lum BL, Fisher GA, Brophy NA. Ehsan MN, Halsey J and Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance J Clin Oncol 12: 835-842
4. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7: 353
5. Bender KS, Shematek JP, Leventhal BG and ET AL (1984) QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 105: 442-444
6. Chapman AE and Goldstein LJ (1995) Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol 22: 17-28
7. Clavel M, Sarkany M, Catimel G, Dumortier A, Guastalla JP, Ardiel C, Lucas C and Bizzari JP (1993) Phase I trial of S9788 in combination with adriamycin as a new multidrug resistance reverser in solid tumors. (Abstract) Proc Am Assoc Cancer Res 34: 231
8. Cros S, Guilbaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G and Bizzari JP (1992) In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivate S9788 in P388/VCR leukemia model Cancer Chemother Pharmacol 30: 491-494
9. De Valeriola D, Brassinne C, Lucas S, Gerard B, Tueni E, Awada A, Parmentier N, Bleiberg H, Piccart M (1997) Lack of interference of S9788 with the pharmacokineties of doxorubicin. Cancer Chemotherapy Pharmacology (in press)
10. Efferth T, Dunn TA, Berlion M, Langenbahn H, Pomnierenke EW and Volm M (1993) Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S9788. Anticancer Res 13: 905-908
11. Frytak S, Mortel CG, Schutt AJ, Hahn RG and Reitemeier RJ (1975) Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer. Cancer Chemother Rep 59: 405-409
12. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124
13. Goncalves E, Sarkany M, Da Costa L, Fadel E, Theodore C, Lucas C, Giroux B and Armand JP (1995) S9788, new multidrug resistance reversing agent: phase I study of a 6 hour continuous infusion in combination with doxorubicin in patients with refractory cancer. (Abstract) Proc Am Soc Clin Oncol 14: 182
14. Hill BT, Van Der Graaf WTA, Hosking LK, De Vries EGE, Mulder NH and Whelan RDH (1993) Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro, Int J Cancer 55: 330-337
15. Huet S, Chapey C and Robert J (1993) Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer 29A: 1377-1383
16. Julia AM, Roche H, Berlion M, Milano G. Robert J, Bizzari JP and Canal P (1994) Multidrug resistance circumvention by a new triazinoanminopiperidine derivate S9788 in vitro: definition of the optimal schedule and comparison with verapamil. Br J Cancer 69: 868-874
17. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I and Gottesman MM (1989) MDRI RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81: 844-849
18. Kramer R, Weber TK, Morse B, Staniunas R, Steele G, Jr and Summerhayes IC (1993) Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 67: 959-968
19. Lai GM, Chen YN, Mickley LA, Fojo AT and Bates SE (1991) P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49: 696-703
20. Leonce S, Pierre A, Anstett M, Perez V, Genton A, Bizzari JP and Atassi G (1992) Effects of a new triazinoaminopiperidine derivate on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol 44: 1707-1715
21. Merlin JM, Guerci A, Marchal S, Missoum N, Ramacci C, Humbert JC, Tsuruo T and Guerci O (1994) Comparative evaluation of S9788, verapamil, and cyclosporin A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84: 262-269
22. Pennock GD, Dalton WS. Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP and Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105-110
23. Perez V, Pierre A, Leonce S, Anstett M and Atassi G (1993) Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxoruhicin. Anticancer Res 13: 985-990
24. Pierre A, Dunn TA, Kraus-Berthier L, Leonce S, Saint-Dizier D, Regnier G, Dhainaut A. Berlion M, Bizzari JP and Atassi G (1992). In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 10: 137-148
25. Raderer M and Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72: 3553-3563
26. Redmond SMS, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G and Cerny T (1991) Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51: 2092-2097
27. Roninson IB (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43: 95-102
28. Scheithauer W, Schenk T and Czejka M (1993) Pharmacokinetic interaction between epirubiein and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68: 8-9
29. Schwartz CL, Hobbie WL, Truesdell S, Constine LC and Clark EB (1993) Corrected QT interval prolongation in anthracyeline-trented survivors of childhood cancer. J Clin Oncol 11: 1906-1910
30. Sebille S, Morjani H, Poullain MG and Manfait M (1994) Effect of S9788. cyclosporin A and verapamil on intracellular distribution of THP-doxoruhicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry. Anticancer Res 14: 2389-2394
31. Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP and Calvo F (1995) In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells - reversal of multidrug resistance by sera from phase I treated patients. Cancer Chemother Pharmacol 36: 195-203
32. Stinson JC, Pears JS, Williams AJ and Campbell RWF (1995) Use of 24 th ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol 39: 651-656
33. Surawicz B and Knoebel SB (1984) Long QT: good, bad or indifferent ? JACC 4: 398-413
34. Terrel C, Le Cesne A, Lagarde N, Di Palma M, Goncalves E, N'Dom P, Yataghene Y, Funck-Brentano C, N'Guyen JP, Marino JP, Besse B. Armand JP, Le Chevalier T, Belpomme D, Misset JL. D'Agay L, Berger L, Sarkany M, Giroux B (1996) S9788 a multidrug resistance (MDR) reversing agent: French phase 1 studies with a 6 hour continuous infusion schedule in combination with chemotherapy in patients with refractory cancer. (Abstract) Proc Am Assoc Cancer Res 37: 165-166
35. Tokaz LK and Von Hoff DD (1984) The cardiotoxicity of anticancer agents. In: Toxicity of Chemotherapy, Perry MC and Yarbro JW (eds) pp. 199-226. Grune & Stratton: Orlando, FL, USA.
36. Yagoda A, Abirached B and Petrylak D (1995) Chemotherapy for advanced renalcell carcinoma: 1983-1993. Semin Oncol 22: 42-60
37. Yamaoka K, Nakagawa T and Uno T (1978) Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165